[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metastatic-pancreatic-adenocarcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metastatic-pancreatic-adenocarcinoma":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,39,73,98,125,146,170,193,214,236,260,281,304,326],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100053774","phase-1-a-phase-1-trial-of-safety-and-initial-efficacy-of-vagal-nerve-blockade-for-cancer-induced-cachexia-in-patients-with-metastatic-pancreatic-adenocarcinoma-100053774",false,"NCT07700212","A Phase 1 Trial Of Safety And Initial Efficacy Of Vagal Nerve Blockade For Cancer-Induced Cachexia In Patients With Metastatic Pancreatic Adenocarcinoma","Inclusion Criteria:\n\n* Patients with metastatic pancreatic cancer.\n* Must have adenocarcinoma component (presence of combined histology is acceptable, as long as adenocarcinoma is present).\n* Weight loss from baseline of at least 5% (Baseline weight can be anytime from diagnosis onward).\n* Must have a tissue-based confirmation of diagnosis available. Tissue does not need to be a metastasis; primary tumor or prior surgery are acceptable sources.\n* Must have had progression of disease after one prior line of therapy in the metastatic setting.\n* Must be receiving or plan to receive another line of therapy in the metastatic setting. o If therapy is being administered outside MD Anderson, the patient is still eligible for this trial. o Enrollment onto a therapeutic clinical trial as this second line therapy is not explicitly excluded.\n* Must have triple ECG results available. Patients will be ineligible if they present: o Second- or third-degree block.\n\n  * Prolonged QT wave.\n  * Atrial fibrillation or flutter.\n  * Uncontrolled ventricular fibrillation or flutter.\n  * Premature ventricular contractions (PVC).\n\nExclusion Criteria:\n\nExclusion Criteria\n\n* History of cervical vagotomy on the right side of neck.\n* Known structural abnormalities on the right side of neck, including but not limited to situs inversus, bulky R-neck lymphadenopathy, etc., that in the investigators' opinion would lead to inability to correctly place the device onto the vagus nerve.\n* Implanted electrical device that passes through the neck (e.g.: cranial implant with battery pack in chest, and wires running through the neck).\n* Metal implants in the neck, including the cervical spine.\n* Recent (6 months or less) nerve block or botox injections to the head or neck.\n* Pain specifically localized to the treatment area, the right side of the neck.\n* Prior severe cerebrovascular disease (e.g., intracranial aneurysm, intracranial hemorrhage, stroke).\n* Prior severe cardiac disease, including but not limited to coronary artery disease (CAD), prior myocardial infarction (MI), uncontrolled congestive heart failure (CHF).","ALL","18 Years",{"count":18,"type":19},10,"ESTIMATED","INTERVENTIONAL",[22],"PHASE1","The goal of this clinical research study is to learn about the safety and tolerability of the OnVagus device when used by patients who have metastatic pancreatic cancer and are receiving chemotherapy.",[25],"Metastatic Pancreatic Adenocarcinoma","NOT_YET_RECRUITING","2026-07-08",{"date":29,"type":30},"2026-07-13","ACTUAL",{"date":32,"type":19},"2026-09-30",{"date":34,"type":19},"2028-12-30",{"name":36,"class":37},"M.D. Anderson Cancer Center","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":20,"phases":48,"briefSummary":50,"conditions":51,"keywords":54,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100624410","phase-3-a-study-to-evaluate-the-effectiveness-and-safety-of-setidegrasib-given-with-either-mfolfirinox-or-nalirifox-chemotherapies-in-people-with-pancreatic-cancer-100624410","NCT07409272","A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer","A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ASP3082 in Combination With mFOLFIRINOX or NALIRIFOX as First-line Treatment in Participants With KRAS G12D Mutated Metastatic Pancreatic Adenocarcinoma","Inclusion Criteria:\n\n* Participant has histologically confirmed metastatic pancreatic ductal adenocarcinoma (PDAC) with documented Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutation based on local or central testing (confirmation of a participant's positive KRAS G12D mutation result must be available prior to randomization).\n* Participant has no option for surgical resection or radiotherapy with curative intent.\n* Participant consents to and provides a baseline tumor tissue specimen for the study during screening. The sample must meet the requirements described in the laboratory manual and the tumor sample guidance.\n* Participant has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 within 7 days prior to randomization.\n* Participant has adequate organ function as indicated by the following laboratory values within 7 days prior to randomization (if a participant has received a recent blood transfusion, the latest laboratory tests must be obtained ≥ 14 days after any blood transfusion). The laboratory values prior to the initiation of the first dose of setidegrasib\u002Fplacebo (or mFOLFIRINOX\u002FNALIRIFOX, if chemotherapy is administered during the screening period) should be used to determine eligibility. Participants who receive mFOLFIRINOX\u002FNALIRIFOX during the screening period must meet these criteria within 7 days prior to the start of on-treatment chemotherapy (i.e., C1D1).\n* Participant agrees not to participate in another interventional study while receiving study intervention in the present study (participant who is currently in the follow-up period of an interventional clinical trial is allowed).\n\nExclusion Criteria:\n\n* Participant has neuroendocrine, acinar pancreatic carcinoma or pancreatic cancer with squamous\u002Fadenosquamous features.\n* Participant has another prior malignancy active (i.e., requiring treatment, including hormonal therapies, or intervention) within the previous 2 years different from the primary malignancy for this study, except for local malignancies that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix or breast, which are allowed.\n* Participant has chronic inflammatory bowel disease, bowel obstruction and\u002For severe uncontrolled diarrhea.\n* Participant has peripheral sensory neuropathy with functional impairment.\n* Participant has ascites and\u002For pleural effusion that require invasive interventions within 30 days prior to randomization or have an indwelling drainage catheter.\n* Participant has symptomatic pulmonary embolism or pulmonary embolism not being treated with anticoagulation.\n* Participant has a history of interstitial lung disease or pulmonary fibrosis.\n* Participant has uncontrolled seizure disorder or refractory to antiepileptics.\n* Participant has known homozygous uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism.\n* Participant has had a myocardial infarction, unstable angina or coronary artery bypass surgery within 6 months prior to randomization or currently has an uncontrolled illness including but not limited to symptomatic congestive heart failure, clinically significant cardiac disease (e.g., cardiomyopathy, infiltrative cardiac disease, etc.), unstable angina pectoris, cardiac arrhythmia, obligate use of a cardiac pacemaker or long QT interval (QT) syndrome.\n* Participant has received any prior systemic therapy for their metastatic PDAC (except with up to 2 doses \\[i.e., 28 days; 1 cycle\\] of mFOLFIRINOX or NALIRIFOX during the screening period. If a participant received \\[neo\\]adjuvant chemotherapy, tumor recurrence or disease progression must have occurred ≥ 6 months after completing the last dose of the \\[neo\\]adjuvant therapy).\n* Participant has had prior treatment with a KRAS G12D-targeted agent.\n* Participant has a corrected QT interval by Fridericia (QTcF) (single electrocardiogram \\[ECG\\]) \\> 470 msec during the screening period.",{"count":47,"type":19},614,[49],"PHASE3","Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic). The standard treatment is chemotherapy, but other treatments are needed to improve outcomes in people with pancreatic cancer. The first treatment that people usually receive is chemotherapy. At the time this study started, some of the main standard chemotherapies for pancreatic cancer were mFOLFIRINOX or NALIRIFOX.\n\nGenes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in certain genes, making them faulty. Many people with pancreatic cancer have a faulty KRAS gene. One such change in the KRAS gene is called a G12D mutation. Researchers are looking for ways to stop the actions of abnormal proteins made from the KRAS G12D mutation.\n\nThis study is about setidegrasib given with chemotherapy in people with pancreatic cancer who have the KRAS G12D mutation. Before setidegrasib can become an approved treatment, clinical studies need to be completed to understand how it works and how safe it is.\n\nThe main aim is to learn if people who are given setidegrasib with chemotherapy live for longer than people who are given placebo with chemotherapy. Other aims are to learn if setidegrasib delays the cancer and symptoms returning, how the body processes setidegrasib, and its safety, when given with chemotherapy.\n\nPeople in this study will be adults with metastatic pancreatic cancer with the G12D mutation in their KRAS gene. Surgery or radiotherapy will not be an option to cure their cancer.\n\nPeople cannot take part if the cancer cells have spread to the thin tissue covering the brain and spinal cord (leptomeningeal disease), have symptoms of cancer in the brain or nervous system, or have recently had some other cancers that required treatment.\n\nIn this study, people are given either setidegrasib with mFOLFIRINOX or NALIRIFOX chemotherapy, or a placebo with mFOLFIRINOX or NALIRIFOX chemotherapy. Whether people receive setidegrasib or placebo is decided by chance. The study doctor decides which chemotherapy (mFOLFIRINOX or NALIRIFOX) people receive. People will only receive NALIRIFOX chemotherapy (with setidegrasib or placebo) after the safety of setidegrasib with NALIRIFOX chemotherapy has been confirmed in another ongoing setidegrasib study. All of the study treatments are given slowly through a tube into a vein (infusion). People will continue to receive study treatment until their cancer gets worse, they can't tolerate the study treatment, they start other cancer treatment, they or the doctor decides the person should stop receiving study treatment, or sadly they pass away. There will be safety checks at each visit, and the doctors will continue to check for medical problems and people's wellbeing throughout the study.",[52,53,25],"Pancreatic Cancer","Metastatic Pancreatic Cancer",[52,53,25,55,56,57,58,59,60],"ASP3082","setidegrasib","KRAS G12D","PDAC","mFOLFIRINOX","NALIRIFOX","RECRUITING","2026-06-24",{"date":64,"type":30},"2026-06-25",{"date":66,"type":30},"2026-02-17",{"date":68,"type":19},"2029-08-31",{"name":70,"class":71},"Astellas Pharma Global Development, Inc.","INDUSTRY",34,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":20,"phases":82,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100610382","phase-2-bms-986340-in-combination-with-nivolumab-gemcitabine-and-nab-paclitaxel-for-the-treatment-of-metastatic-and-recurrent-pancreatic-adenocarcinoma-100610382","NCT07226856","BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma","Phase 2, Single-Arm Trial of BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-Paclitaxel in the First Line Setting of Advanced Pancreatic Adenocarcinoma","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Histological confirmation of pancreatic adenocarcinoma\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1\n* Initial diagnosis of metastatic or recurrent disease (per American Joint Committee on Cancer 8th Edition \\[AJCC 8th edition 2018\\])\n* Electrocardiogram (ECG) without any clinically significant findings (QT interval corrected by Fridericia's formula (QTcF) ≤ 450 msec and no known arrhythmias) and per the investigator's assessment\n* Hemoglobin ≥ 9.0 g\u002FdL (≤ 15 days prior to registration) (transfusion to achieve this level is not permitted prior to registration)\n* White blood cells (WBC) ≥ 2000\u002FuL (≤ 15 days prior to registration)\n* Absolute neutrophil count (ANC) ≥ 1500\u002Fmm\\^3 (≤ 15 days prior to registration) (stable off any growth factor prior to registration)\n* Platelet count ≥ 100,000\u002Fmm\\^3 (≤ 15 days prior to registration) (transfusion to achieve this level is not permitted prior to registration)\n* Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (≤ 15 days prior to registration) except in patients with documented Gilbert's syndrome, who must have a total bilirubin ≤ 3 x ULN\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x institution's upper limit of normal (ULN) for patients with no concurrent liver metastases, OR ≤ 5.0 x institution's ULN for patients with concurrent liver metastases (≤ 15 days prior to registration)\n* Prothrombin time (PT)\u002Finternational normalized ratio (INR)\u002Factivated partial thromboplastin time (aPTT) ≤ 1.5 x ULN (≤ 15 days prior to registration) OR if patient is receiving anticoagulant therapy and INR or aPTT is within target range of therapy\n* Calculated creatinine clearance ≥ 40 ml\u002Fmin using the Cockcroft-Gault formula (≤ 15 days prior to registration)\n* Negative pregnancy test done ≤ 8 days prior to registration, for persons of childbearing potential only\n* Provide written informed consent\n* Willingness to provide mandatory blood specimens for correlative research\n* Willingness to provide mandatory tissue specimens for correlative research\n* Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)\n\nExclusion Criteria:\n\n* Any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects:\n\n  * Pregnant persons\n  * Nursing persons\n  * Participants of childbearing potential who are unwilling to employ adequate contraception\n* Failure to recover from any adverse events related to any of the following therapies received prior to registration:\n\n  * Minor surgical or interventional procedure\n  * Major surgical procedure other than diagnostic surgery, ≤ 28 days prior to registration\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Uncontrolled intercurrent illness including, but not limited to:\n\n  * Ongoing or active infection\n  * Symptomatic congestive heart failure ≤ 6 months prior to registration\n  * Unstable angina pectoris ≤ 6 months prior to registration\n  * Cardiac arrhythmia\n  * Coronary stenting or myocardial infarction ≤1 year prior to registration\n  * Dyspnea at rest due to complications of advanced malignancy or other disease that requires continuous oxygen therapy\n  * Psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n  * Known historical or active infection with hepatitis B, or active infection with hepatitis C (note that subjects with hepatitis C who have been clinically cured, defined as persistent absence of hepatitis C ribonucleic acid \\[RNA\\] detected by polymerase chain reaction \\[PCR\\] test in serum 12 weeks after completing antiviral treatment, are eligible for this study)\n  * Active infection or an unexplained fever \\> 38.5°C during screening visits or on the first scheduled day of dosing (at the discretion of the investigator, subjects with tumor fever may be enrolled), which in the investigator's opinion might compromise the subject's participation in the study or affect the study outcome\n  * Interstitial lung disease, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies\n  * Peripheral artery disease (e.g. claudication, Leo Buerger's disease)\n* Neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma\n* Known human immunodeficiency virus (HIV) positive with an acquired immune deficiency syndrome (AIDS)-defining opportunistic infection within the last year, or a current CD4 count \\\u003C 350 cells\u002FuL. Participants with HIV are eligible if:\n\n  * They have received antiretroviral therapy for ≥ 4 weeks prior to the first dose of study treatment\n  * They continue on antiretroviral therapy as clinically indicated while enrolled on study\n  * CD4 counts and viral load are monitored per standard of care by a local health care provider\n* Prior treatment of PDAC with chemotherapy in the neoadjuvant and\u002For adjuvant setting, except those where at least 12 months have elapsed since completion of the last dose and no persistent treatment-related toxicities are present\n* Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm\n* Other active malignancy ≤ 5 years prior to registration. Participants with any of the following additional malignancies are not excluded:\n\n  * Malignancies with negligible risk of metastases or death (e.g., risk of death or metastases \\\u003C 5% at 5 years) that were treated with curative intent and have not recurred within the past 2 years prior to study day 1\n  * Completely resected basal cell or squamous cell skin cancers, carcinoma in situ (CIS) of the cervix, or ductal CIS of the breast\n  * Malignancies considered to be indolent and never required therapy (immunotherapy, chemotherapy, radiation)\n  * Malignancies treated with hormonal therapy alone\n* History of myocardial infarction ≤ 6 months prior to registration, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias\n* Prior treatment of pancreatic cancer in the metastatic setting with surgery, radiotherapy, chemotherapy or investigational therapy:\n\n  * Palliative radiotherapy is permitted\n  * Placement of biliary stent\u002Ftube is permitted\n* Documented serum albumin \\\u003C 3 g\u002FdL ≤ 15 days prior to registration\n* Known history of central nervous system (CNS) metastases\n* Active, known, or suspected autoimmune disease (type 1 diabetes mellitus, hypothyroidism only requiring hormone replacement)\n* Systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalent) ≤ 14 days or other immunosuppressive medications ≤ 30 days prior to registration\n* Prior therapy with anti-PD-1, anti-PD-L1, anti-CTLA-4, anti-CCR8 antibody\n* Malignant disease other than that being treated in this study\n* Receipt of an allogeneic tissue\u002Fsolid organ transplant\n* Any other clinically significant disease or comorbidity that may adversely affect the safe delivery of treatment within this trial or may limit compliance with study requirements in the opinion of the Investigator\n* Known hypersensitivity to BMS-986340 or its metabolites and\u002For excipients and known hypersensitivity to any component of the regimens, their metabolites and\u002For excipients being used in the combination therapy cohorts for which the participant is being considered\n* Unwillingness to follow study related procedures",{"count":81,"type":19},43,[83],"PHASE2","This phase II trial tests the safety, side effects and best dose of BMS-986340 in combination with nivolumab, gemcitabine, and nab-paclitaxel and how well it works in treating patients with pancreatic adenocarcinoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that has come back after a period of improvement (recurrent). BMS-986340 is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid and may kill tumor cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. Giving BMS-986340 in combination with nivolumab, gemcitabine, and nab-paclitaxel may be safe, tolerable, and\u002For effective in treating patients with metastatic or recurrent pancreatic adenocarcinoma.",[25,86,87],"Recurrent Pancreatic Adenocarcinoma","Stage IV Pancreatic Cancer AJCC v8","2026-06-05",{"date":90,"type":30},"2026-06-09",{"date":92,"type":30},"2025-12-12",{"date":94,"type":19},"2028-12-01",{"name":96,"class":37},"Mayo Clinic",3,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":20,"phases":107,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":38},"100637571","phase-1-ab801-in-combination-with-chemotherapy-and-immunotherapy-for-the-treatment-of-patients-with-borderline-resectable-locally-advanced-or-metastatic-cholangiocarcinoma-or-pancreatic-cancer-100637571","NCT07619313","AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer","A Phase 1\u002F1b Trial of AB801 in Combination With Chemotherapy and PD-1\u002FPD-L1 Blockade in Patients With Cholangiocarcinoma or Pancreatic Adenocarcinoma","Inclusion Criteria:\n\n* Male or female ≥ 18 years of age and willing and able to provide informed consent\n* Previously untreated cytologically or histologically confirmed, at least one measurable lesion via Response Evaluation Criteria in Solid Tumors (RECIST 1.1) of cholangiocarcinoma or pancreatic adenocarcinoma meeting following criteria:\n\n  * Cholangiocarcinoma\n\n    * Borderline resectable\u002Flocally advanced cholangiocarcinoma: to be defined as unresectable disease on evaluation by a hepatobiliary multi-disciplinary tumor board\u002Fsurgeon based on tumor size\u002Flocation, vascular involvement, and absence of extrahepatic metastasis.\n    * Metastatic cholangiocarcinoma: Patients with metastatic cholangiocarcinoma patient who have not received prior systemic therapy\n  * Pancreatic adenocarcinoma\n\n    * Borderline resectable pancreatic adenocarcinoma: There are multiple definitions of borderline resectable pancreatic ductal adenocarcinoma (PDAC). For the purposes of this study, borderline resectable disease will be identified per the National Comprehensive Cancer Network (NCCN) criteria. Per this definition, borderline resectable PDAC is defined as the presence of any one or more of the following on CT:\n\n      * An interface between the tumor and superior mesenteric artery (SMA) or celiac axis (CA) measuring \\\u003C 180º of the circumference of the vessel wall.\n      * An interface between the tumor with the common hepatic artery without extension into the celiac axis or hepatic artery bifurcation allowing for safe and complete resection and reconstruction.\n      * An interface between the primary tumor and the superior mesenteric vein or portal vein (SMV-PV) measuring ≥ 180° of the circumference of the vessel wall\n      * Short-segment occlusion of the SMV-PV with normal vein above and below the level of obstruction that is amenable to resection and venous reconstruction\n      * An interface between the primary tumor and the inferior vena cava (IVC)\n    * Locally advanced pancreatic adenocarcinoma: Multiple guidelines defining locally advanced PDAC have been developed. For the purposes of this study, locally advanced PDAC cases will be identified per the definition developed by the NCCN. Per this definition, locally advanced PDAC is defined as presence of any one or more of the following on CT:\n\n      * Interface between the tumor and SMA or CV measuring \\> 180º of the circumference of the vessel wall or solid tumor contact with the CA and aortic involvement.\n      * Occlusion of the SMV-PV that is not amenable to resection and venous reconstruction\n  * Metastatic pancreatic adenocarcinoma: Patients with metastatic pancreatic adenocarcinoma who have not received prior systemic therapy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Absolute neutrophil count (ANC) ≥ 1.5x10\\^9\u002FL\n* Platelets ≥ 100x10\\^9\u002FL\n* Hemoglobin ≥ 9 g\u002FdL\n* Creatinine clearance (Ccr) ≥ 50 mL\u002Fmin (as calculated by Modified Cockcroft-Gault formula)\n* Serum total bilirubin ≤ 2x upper limit of normal (ULN) or \\\u003C 3x ULN if Gilbert's syndrome\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\]) and alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase \\[SGPT\\]) ≤ 2.5 X ULN; \\\u003C 5x ULN in patients with liver metastases\n* Women with no childbearing potential because of surgery or who are at least 1 year postmenopausal (ie, 12 months post last menstrual period) or with menopause confirmed by follicle-stimulating hormone testing, OR\n* Women of childbearing potential (defined as any female who has experienced menarche and is not permanently sterile or post-menopausal) must use an effective nonhormonal method of contraception (intrauterine device or intrauterine system; condom or occlusive cap \\[diaphragm or cervical or vault caps\\] with spermicidal foam or gel or film or cream or suppository; or vasectomized male partner if he is the sole partner of that participant) or practice true abstinence for the duration of the study and for up to 14 months after the last systemic treatment\n* Male participants must use an effective method of contraception (condom or occlusive cap \\[diaphragm or cervical or vault caps\\] with spermicidal foam or gel or film or cream or suppository; or vasectomy) or practice true abstinence as defined throughout the study and for up to 11 months after the systemic treatment\n* Immunosuppressive doses of systemic medications, such as corticosteroids or absorbed topical corticosteroids (doses \\> 10 mg\u002Fday prednisone or equivalent) must be discontinued at least 2 weeks (14 days) before study treatment administration. Physiologic doses of corticosteroids (≤ 10 mg\u002Fday of prednisone or its equivalent) or short pulses of corticosteroids (≤ 3 days) may be permitted\n* Products with known potential to prolong the corrected QT (QTc) interval should be avoided when possible. When able will replace non-prolonging QTc acting drug when available and if medically necessary\n* Major surgery as defined by the Investigator must be completed at least 4 weeks before study treatment administration. Participants should have recovered from the surgical procedure prior to the first dose being administered\n* Adequate baseline tumor tissue sample for correlative studies\n\nExclusion Criteria:\n\n* Previous treatment with any of planned study drugs in cholangiocarcinoma, though patients with one cycle of gemcitabine\u002Fcisplatin\u002Fdurvalumab will be considered eligible\n* Previous treatment with any of planned study drugs in pancreatic adenocarcinoma, though patients with one cycle of FOLFIRINOX will be considered eligible\n* Peripheral neuropathy \\> grade 2\n* Known status of HIV which is not well-controlled (CD4 \\\u003C 300) at the time of study eligibility. Patients with controlled and treated HIV\u002Fhepatitis C virus (HCV) and an undetectable viral load are allowed\n* Untreated hepatitis B infection; Patient has known active hepatitis B virus (HBV) or hepatitis C virus (HCV), or human immunodeficiency virus (HIV) infection (testing is not mandatory, unless known active or known history of infection or required by local regulation):\n\n  * Participants with resolved or treated HCV (ie, HCV antibody positive but undetectable HCV ribonucleic acid \\[RNA\\]) will not be excluded from this study\n* Underlying medical conditions that, in the Investigator's opinion, will make the administration of investigational product (IP)(s) hazardous, including but not limited to:\n\n  * Interstitial lung disease, including history of interstitial lung disease or non-infectious pneumonitis\n  * Active viral, bacterial, or fungal infections requiring parenteral treatment within 14 days of the initiation of the IP,\n  * Active infection or antibiotics within 48 hours prior to study screening;\n  * A condition or unresolved adverse event (AE) from a prior investigational drug that may obscure the interpretation of toxicity determination or AEs,\n  * History of prior solid-organ transplantation\n* Any history of malignancy less than 5 years prior to the time of study eligibility (Patients with history of skin cancers excluding melanoma and cancers with a very low risk of recurrence i.e., low grade prostate cancer, thyroid cancer and low risk cervical cancer will be eligible for participation)\n* Serious medical comorbidities such as New York Heart Association Class III\u002FIV cardiac disease, uncontrolled cardiac arrhythmias, myocardial infarction over the past 12 months\n* Known family history or personal history of long QTc syndrome or previous drug-induced QTc prolongation of at least grade 3 (QTc \\> 500 ms)\n* Screening 12-lead electrocardiogram (ECG), in triplicate, with a measurable QTc interval of \\> 450ms\n* Known, existing uncontrolled coagulopathy. Patients who have had a venous thromboembolic event (e.g., pulmonary embolism or deep vein thrombosis) requiring anticoagulation are eligible IF: they are appropriately anticoagulated and have not had a grade 2 or greater bleeding episode in the 3 weeks before day 1\n* Known pregnancy, nursing women or positive pregnancy test. Requirement for women of childbearing potential (WOCBP): Negative serum pregnancy test at screening and serum or urine prior to dosing on cycle 1 day 1, within 24 hours prior to the start of treatment (minimum sensitivity 25 IU\u002FL or equivalent units of human chorionic gonadotropin \\[HCG\\]). WOCBP must also have a negative serum or urine pregnancy test every 3 weeks, within 24 hours prior to the start of treatment\n* Any condition (concurrent disease, infection, or comorbidity) that interferes with ability to participate in the study, causes undue risk, or complicates the interpretation of safety data, in the opinion of the investigator\n* History of trauma or major surgery within 28 days prior to the first dose of IP\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\n* Any active or documented history of autoimmune disease, including but not limited to inflammatory bowel disease, celiac disease, Wegner syndrome, Hashimoto syndrome, systemic lupus erythematosus, scleroderma, sarcoidosis, or autoimmune hepatitis, within 3 years of the first dose of study treatment, except for the following:\n\n  * Type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders such as vitiligo, or alopecia not requiring systemic therapy, or conditions not expected to recur in the absence of an external trigger.\n  * Endocrinopathies where the participant is stable on hormone replacement therapy\n  * History of Hashimoto syndrome within 3 years of the first of study treatment that resolved to hypothyroidism alone",{"count":106,"type":19},46,[22],"This phase I trial tests the safety, side effects, best dose and effectiveness of AB801 in combination with chemotherapy and immunotherapy in treating patients with cholangiocarcinoma or pancreatic adenocarcinoma that may be removed by surgery (borderline resectable), that has spread to nearby tissue or lymph nodes (locally advanced), or that has spread from where it first started (primary site) to other places in the body (metastatic). AB801 is a drug designed to block a protein called AXL. AXL is found on the surface of certain cancer cells and plays an important role in helping tumors grow, spread to other parts of the body, and avoid the immune system. It is thought to contribute to resistance against common cancer treatments such as chemotherapy, radiation and immunotherapy. In many cancers, including cholangiocarcinoma and pancreatic adenocarcinoma, AXL is overactive and associated with worse outcomes. AB801 inhibits AXL which may make cancer cells more sensitive to chemotherapy and allow immune cells to better recognize and attack the tumor. Chemotherapy drugs, such as gemcitabine, cisplatin, oxaliplatin, irinotecan, leucovrin and fluorouracil, work in different ways to stop the growth of cancer cells either by killing the cells, by stopping them from dividing or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as durvalumab and zimberelimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving AB801 in combination with chemotherapy and immunotherapy may better treat patients with borderline resectable, locally advanced or metastatic cholangiocarcinoma or pancreatic adenocarcinoma.",[110,111,112,113,25,114,115,87],"Borderline Resectable Pancreatic Ductal Adenocarcinoma","Locally Advanced Cholangiocarcinoma","Locally Advanced Pancreatic Adenocarcinoma","Metastatic Cholangiocarcinoma","Stage II Pancreatic Cancer AJCC v8","Stage III Pancreatic Cancer AJCC v8","2026-06-02",{"date":118,"type":30},"2026-06-04",{"date":120,"type":19},"2026-06-01",{"date":122,"type":19},"2028-06-01",{"name":124,"class":37},"Jonsson Comprehensive Cancer Center",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":20,"phases":134,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":38},"100638164","phase-1-64cu-dota-a2-scfv-fc2-dm-with-positron-emission-tomography-for-the-imaging-of-patients-with-locally-advanced-or-metastatic-psca-expressing-pancreatic-cancer-100638164","NCT07608627","64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer","A Phase 1 Clinical Trial of 64Cu-DOTA A2 scFv-Fc2 DM (64Cu-DOTA-A2DM) Positron Emission Tomography in Patients With Metastatic PSCA-Expressing Pancreatic Cancer","Inclusion Criteria:\n\n* Documented informed consent of the participant and\u002For legally authorized representative\n* Age: ≥ 18 years\n* Karnofsky \\> 70%\n* Advanced (locally or metastatic), histologically confirmed pancreatic adenocarcinoma\n* Evidence of locally advanced unresectable or metastatic disease demonstrated by an abnormal imaging scan (computed tomography \\[CT\\], magnetic resonance imaging \\[MRI\\], fludeoxyglucose \\[FDG\\]-PET) within 8 weeks prior to enrollment\n* No prior radiation therapy to target lesions\n* Hemoglobin ≥ 9g\u002FdL\n\n  * NOTE: Red blood cell transfusions are not permitted within 14 days of hemoglobin assessment unless cytopenia is secondary to disease involvement\n* Total bilirubin ≤ 1.5 X upper limit of normal (ULN) (unless has Gilbert's disease)\n* Aspartate aminotransferase (AST) ≤ 3.0 x ULN\n* Alanine aminotransferase (ALT) ≤ 3.0 x ULN\n* Serum creatinine \\\u003C 1.4 mg\u002FdL\n* Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* Agreement by females and males of childbearing potential\\* to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 months after the last dose of protocol therapy.\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \\> 1 year (women only)\n\nExclusion Criteria:\n\n* Chemotherapy, radiation therapy, biological therapy, immunotherapy within 14 days or five half-lives (whichever is shorter for non-radiation therapy) prior to day 1 of protocol therapy\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent\n* Clinically significant uncontrolled illness\n* Other active malignancy. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n* Females only: Pregnant or breastfeeding\n* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics)",{"count":133,"type":19},15,[22],"This clinical trial tests the safety, side effects, best dose and feasibility of using 64Cu-DOTA A2 scFv-Fc2 DM with positron emission tomography for the imaging of patients with PSCA-expressing pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 64Cu-DOTA A2 scFv-Fc2 DM. Because PSCA expressing pancreatic cancers take up 64Cu-DOTA A2 scFv-Fc2 DM it can be seen with PET. A PET scan is a procedure in which a small amount of radioactive glucose (sugar) is injected into a vein, and a scanner is used to make detailed, computerized pictures of areas inside the body where the glucose is taken up. Because cancer cells often take up more glucose than normal cells, the pictures can be used to find cancer cells in the body. Using 64Cu-DOTA A2 scFv-Fc2 DM with positron emission tomography may be a safe and feasible way to obtain diagnostic images of patients with locally advanced or metastatic PSCA-expressing pancreatic cancer.",[112,25,115,87],"2026-05-20",{"date":139,"type":30},"2026-05-27",{"date":141,"type":19},"2026-12-16",{"date":143,"type":19},"2028-07-14",{"name":145,"class":37},"City of Hope Medical Center",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":20,"phases":155,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":169},"100592861","phase-3-studying-chemotherapy-with-or-without-panitumumab-for-unresectable-locally-advanced-or-metastatic-pancreatic-cancer-without-kras-mutations-100592861","NCT06998940","Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations","Randomized Phase III Study of Second-Line Chemotherapy With or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma","Inclusion Criteria:\n\n* Participants must have a histologically or cytologically confirmed diagnosis of ductal adenocarcinoma of the pancreas\n* Participants must have previously documented KRAS wild type (i.e. absence of any KRAS mutation) and BRAF V600E wild type (i.e. absence of a BRAF V600E mutation) status determined by tumor tissue-based NGS assay. The testing must be done within a laboratory with Clinical Laboratory Improvement Act (CLIA), International Organization for Standardization (ISO)\u002FInternational Electrotechnical Commission (IEC), College of American Pathologists (CAP), or similar certification status\n\n  * NOTE: Blood-based next generation sequencing (NGS) assays, such as circulating tumor deoxyribonucleic acid (DNA) (ctDNA) or liquid biopsies, will not be accepted for meeting eligibility criteria\n* Participants must have documented unresectable and\u002For metastatic disease on CT or magnetic resonance imaging (MRI) imaging completed prior to randomization. Imaging must have been completed within 28 days prior to randomization for participants with measurable disease. CT scans or MRIs used to assess non-measurable disease must have been completed within 42 days prior to randomization. All disease must be assessed and documented on the Baseline Tumor Assessment Form (In calculating days of tests and measurements, the day a test or measurement is done is considered Day 0. Therefore, if a test is done on a Monday, the Monday 4 weeks later would be considered Day 28. This allows for efficient participant scheduling without exceeding the guidelines. If Day 14 or 28 falls on a weekend or holiday, the limit may be extended to the next working day)\n* Participants must not have known mutations in PTEN, NRAS, EGFR extracellular domain exons 1-16, no amplifications of HER2 and MET, and no gene fusions of RET, NTRK1, and ALK by tumor tissue-based NGS analysis\n\n  * NOTE: Participants who are not tested for these mutations are eligible if they have previously documented KRAS wild type (i.e. absence of any KRAS mutation) and BRAF V600E wild type (i.e. absence of a BRAF V600E mutation) status\n* Participants must not have known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and\u002For surgery and stable for at least 28 days before randomization (In calculating days of tests and measurements, the day a test or measurement is done is considered Day 0. Therefore, if a test is done on a Monday, the Monday 4 weeks later would be considered Day 28. This allows for efficient participant scheduling without exceeding the guidelines. If Day 14 or 28 falls on a weekend or holiday, the limit may be extended to the next working day).\n\n  * NOTE: Participants must be neurologically asymptomatic and without corticosteroid treatment at the time of enrollment\n* Participants must have received only one line of prior systemic cytotoxic chemotherapy for locally advanced or metastatic PDA, and have radiographically progressed, refractory, or intolerant to this therapy.\n\n  * Prior neoadjuvant or adjuvant therapy with 5-FU or gemcitabine-based chemotherapy counts as a line of therapy if the participant's disease progressed to locally advanced or metastatic disease within 6 months of completing treatment\n  * Participants with cancers harboring molecular alterations including microsatellite instability (MSI-high), elevated tumor mutational burden (TMB) (TMB ≥ 10 mut\u002FMb), and FGFR1-3, NRG1, and ROS fusions are allowed to have received an additional line of targeted therapy applicable to the respective molecular alterations at the treating investigators discretion.\n  * Prior maintenance therapy with Olaparib or Rucaparib for germline or somatic BRCA1\u002F2 or PALB2 mutations does not count as a line of therapy.\n* Participants must not have prior treatment with an anti-EGFR antibody (e.g., cetuximab or panitumumab)\n* Participants must not have prior treatment with an EGFR tyrosine kinase inhibitor (e.g., erlotinib)\n* Participants must not have received any pancreatic anticancer therapy (e.g., standard of care or investigational chemotherapy, molecularly targeted therapy, or radiation) within 14 days prior to randomization\n* Participants must not have a known contraindication to receiving chosen chemotherapy backbone at the planned doses in accordance with the local approved label\n* Participant must be ≥ 18 years old at the time of randomization\n* Participants must have Zubrod performance status of 0-2\n* Participants must have a complete medical history and physical exam within 28 days prior to randomization (In calculating days of tests and measurements, the day a test or measurement is done is considered Day 0. Therefore, if a test is done on a Monday, the Monday 4 weeks later would be considered Day 28. This allows for efficient participant scheduling without exceeding the guidelines. If Day 14 or 28 falls on a weekend or holiday, the limit may be extended to the next working day)\n* Absolute neutrophil count ≥ 1.0 x 10\\^3\u002FuL (within 28 days prior to randomization) (In calculating days of tests and measurements, the day a test or measurement is done is considered Day 0. Therefore, if a test is done on a Monday, the Monday 4 weeks later would be considered Day 28. This allows for efficient participant scheduling without exceeding the guidelines. If Day 14 or 28 falls on a weekend or holiday, the limit may be extended to the next working day)\n\n  * Note: Use of growth factor support (e.g., Granulocyte Colony-Stimulating Factor \\[G-CSF\\] or romiplostim \\[Nplate\\]) is permitted, and prior use does not constitute an exclusion criterion. Recent blood transfusions are also allowed\n* Hemoglobin ≥ 8 g\u002FdL (within 28 days prior to randomization) (In calculating days of tests and measurements, the day a test or measurement is done is considered Day 0. Therefore, if a test is done on a Monday, the Monday 4 weeks later would be considered Day 28. This allows for efficient participant scheduling without exceeding the guidelines. If Day 14 or 28 falls on a weekend or holiday, the limit may be extended to the next working day)\n\n  * Note: Use of growth factor support (e.g., G-CSF or romiplostim \\[Nplate\\]) is permitted, and prior use does not constitute an exclusion criterion. Recent blood transfusions are also allowed\n* Platelets ≥ 75 x 10\\^3\u002FuL (within 28 days prior to randomization) (In calculating days of tests and measurements, the day a test or measurement is done is considered Day 0. Therefore, if a test is done on a Monday, the Monday 4 weeks later would be considered Day 28. This allows for efficient participant scheduling without exceeding the guidelines. If Day 14 or 28 falls on a weekend or holiday, the limit may be extended to the next working day)\n\n  * Note: Use of growth factor support (e.g., G-CSF or romiplostim \\[Nplate\\]) is permitted, and prior use does not constitute an exclusion criterion. Recent blood transfusions are also allowed\n* Total bilirubin ≤ 1.5 x institutional upper limit of normal (IULN) (within 28 days prior to randomization) (In calculating days of tests and measurements, the day a test or measurement is done is considered Day 0. Therefore, if a test is done on a Monday, the Monday 4 weeks later would be considered Day 28. This allows for efficient participant scheduling without exceeding the guidelines. If Day 14 or 28 falls on a weekend or holiday, the limit may be extended to the next working day)\n* Aspartate aminotransferase (AST) ≤ 10 x upper limits of normal (ULN) (within 28 days prior to randomization) (In calculating days of tests and measurements, the day a test or measurement is done is considered Day 0. Therefore, if a test is done on a Monday, the Monday 4 weeks later would be considered Day 28. This allows for efficient participant scheduling without exceeding the guidelines. If Day 14 or 28 falls on a weekend or holiday, the limit may be extended to the next working day)\n* Participants must have a creatinine ≤ the IULN OR measured OR calculated creatinine clearance ≥ 30 mL\u002Fmin using the following Cockcroft-Gault Formula. This specimen must have been drawn and processed within 28 days prior to registration (In calculating days of tests and measurements, the day a test or measurement is done is considered Day 0. Therefore, if a test is done on a Monday, the Monday 4 weeks later would be considered Day 28. This allows for efficient participant scheduling without exceeding the guidelines. If Day 14 or 28 falls on a weekend or holiday, the limit may be extended to the next working day)\n* Participants with known history of human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at registration and have undetectable viral load test on the most recent test results obtained within 6 months prior to randomization\n* Participants with a known history of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load while on suppressive therapy on the most recent test results obtained within 6 months prior to randomization, if indicated\n* Participants with a known history of hepatitis C virus (HCV) infection must have been treated and cured. Participants currently being treated for HCV infection must have undetectable HCV viral load test on the most recent test results obtained within 6 months prior to randomization, if indicated\n* Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the investigational regimen\n* Participants must not be pregnant or nursing (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped). Individuals who are of reproductive potential must have agreed to use an effective contraceptive method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of \"reproductive potential.\" In addition to routine contraceptive methods, \"effective contraception\" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation\u002Focclusion, and vasectomy with testing showing no sperm in the semen\n* Participants must be offered the opportunity to participate in specimen banking\n* Participants who can complete patient reported outcomes (FACT-G and PRO-CTCAE) questionnaires in English or Spanish must be offered the opportunity to participate in the quality-of-life studies\n* Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines.\n\n  * For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations",{"count":154,"type":19},94,[49],"This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil \\[5-FU\\] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine) versus standard chemotherapy alone in treating patients with KRAS wild type (WT) pancreatic ductal adenocarcinoma that cannot be removed by sugery (unresectable) or that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Panitumumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Chemotherapy drugs, such as nanoliposomal irinotecan, leucovorin, 5-FU, irinotecan, nab-paclitaxel and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding panitumumab to standard chemotherapy may be effective in treating patients with unresectable, locally advanced, or metastatic KRAS WT pancreatic ductal adenocarcinoma.",[112,25,115,87,158],"Unresectable Pancreatic Adenocarcinoma","2026-05-19",{"date":161,"type":30},"2026-05-22",{"date":163,"type":30},"2026-05-13",{"date":165,"type":19},"2030-12",{"name":167,"class":168},"SWOG Cancer Research Network","NETWORK",274,{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":20,"phases":180,"briefSummary":181,"conditions":182,"keywords":183,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":186,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":97},"100533721","phase-1-dose-escalation-and-dose-expansion-study-of-gas-in-subjects-with-metastatic-pancreatic-adenocarcinoma-100533721","NCT06229496","Dose Escalation and Dose Expansion Study of GAS in Subjects With Metastatic Pancreatic Adenocarcinoma","A Phase 1b, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of S-1 in Combination With Nab-paclitaxel and Gemcitabine (GAS) in Subjects With Metastatic Pancreatic Adenocarcinoma","GAS","Inclusion Criteria:\n\n1. Histologically or cytologically confirmed pancreatic adenocarcinoma (poorly differentiated carcinoma is allowed in the absence of neuroendocrine features or squamous differentiation)\n2. Treatment-naï ve stage IV disease (measurable disease is required). Prior adjuvant chemotherapy or radiochemotherapy is allowed, if completed ≥ 6 months before enrollment.\n3. Measurable disease defined as at least one lesion that can be measured in at least one dimension (longest diameter to be recorded) as ≥ 10 mm with CT scan or MRI\n4. Eastern Cooperative Oncology Group (ECOG) performance score of 0-1\n5. Life expectancy \\> 6 months in the opinion of his\u002Fher treating physician.\n6. At least 18 years of age\n7. Ability to understand the nature of this study protocol, comply with study and\u002For follow-up procedures, and sign the IRB-approved written informed consent\n8. Fertile female and male patients with child-bearing potential agree to use adequate contraceptive measures prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.\n9. Adequate bone marrow function:\n\n   Absolute neutrophil count (ANC) ≥ 1500\u002FuL Platelet count ≥ 100,000\u002FuL Hemoglobin ≥ 9.0 g\u002FdL\n10. Adequate hepatic function:\n\n    Total bilirubin ≤ 1.5 X ULN (≤3.5 mg\u002FdL if with adequate biliary tract drainage\u002Fstent placement) AST ≤ 3.0 X ULN (≤5.0X ULN if liver metastases are present) ALT ≤ 3.0 X ULN (≤5.0X ULN if liver metastases are present)\n11. Adequate renal function (defined as serum creatinine ≤ 1.5 X ULN or creatinine clearance rate (CCr) ≥ 50 mL\u002Fmin (calculated by Cockroft-Gault formula; male: \\[(140 - age in years) × weight in kg)\\]\u002F\\[72 × serum creatinine(mg\u002FdL)\\];female=male x 0.85 )\n12. Able to take the oral study medication (S-1)\n13. No clinically significant abnormal ECG findings within 28 days (4 weeks) prior to enrollment\n\nExclusion Criteria:\n\n1. Have known endocrine pancreatic tumors or ampullary cancer\n2. Have received first line treatment for metastatic pancreatic cancer\n3. Have a serious concomitant active infection or other major comorbidities that, in the opinion of the investigator, would compromise the patient's ability to adhere to the protocol (e.g., stroke, uncontrolled arrhythmia, heart failure, or active autoimmune disease)\n4. Have HIV history or hepatitis B and C infection, except for prescribing anti-hepatitis B medications for hepatitis B carrier and undetectable HCV RNA level for hepatitis C prior to enrollment.\n5. Have known central nervous system (CNS) malignancy or metastasis (screening is not required)\n6. Have concurrent hematologic malignancies, acute or chronic leukemia\n7. Have known additional malignancy that is progressing or required active treatments within the past 6 months, except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast or cervical cancer)\n8. Women with a positive pregnancy test or who are breastfeeding\n9. Have participated within the last 30 days in a clinical trial involving an investigational product\n10. Unable to swallow capsules or has diseases significantly affecting gastrointestinal function or resection of the stomach or small bowel, malabsorption syndrome, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction.\n11. Current peripheral sensory neuropathy ≥ Grade 2\n12. Any social condition or diseases judged ineligible by physician for participation in the study due to safety concern",{"count":179,"type":19},70,[22],"A Phase 1b, open-label, multicenter, dose escalation and dose expansion study of S-1 in combination with nab-paclitaxel and gemcitabine (GAS) in subjects with metastatic pancreatic adenocarcinoma. This study is a dose escalation and dose expansion study with the objective to establish the MTD and\u002For RP2D and\u002For DLT of nab-paclitaxel and gemcitabine in combination with a body surface area(BSA)-based dose of S-1 in subject with metastatic pancreatic adenocarcinoma.",[25],[184,185,176],"Dose escalation","Pancreatic adenocarcinoma",{"date":161,"type":30},{"date":188,"type":30},"2023-08-01",{"date":190,"type":19},"2028-12-31",{"name":192,"class":37},"Chang Gung Memorial Hospital",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":20,"phases":202,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":38},"100332465","phase-1-iexosomes-in-treating-participants-with-metastatic-pancreas-cancer-with-krasg12d-mutation-100332465","NCT03608631","iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation","Phase I Study of Mesenchymal Stromal Cells-Derived Exosomes With KrasG12D siRNA for Metastatic Pancreas Cancer Patients Harboring KrasG12D Mutation","Inclusion Criteria:\n\n* Patients with histologically confirmed metastatic pancreatic ductal adenocarcinoma harboring KrasG12D mutation\n* Patients must have documented progression or stable disease on one or more lines of systemic therapy. If stable disease, patient must have completed at least 4 months of chemotherapy with cytotoxic therapy\n* KrasG12D mutation status will be informed from any previous routine molecular profiling (using commercial assays such as Foundation One, Caris, Oncomine or other) of tissue or blood. Additional KrasG12D mutation status may be confirmed using tissue biopsy or blood prior to enrolling into the trial\n* ECOG (Eastern Cooperative Oncology Group) performance status of 0-1\n* Absolute neutrophil count (ANC) more or equal to 1,500 cells\u002Fmm3\n* Platelets more or equal to 100,000\u002Ful\n* Hemoglobin more than 9.0 g\u002FdL\n* Total bilirubin between 1 and 1.5 mg\u002FdL\n* AST (aspartate aminotransferase) and ALT (alanine transaminase) less than 2.5 x ULN (upper limit of normal)\n* Alkaline phosphatase less than 2.5 x ULN\n* Creatinine less than 1.5 gm\u002FdL\n* In patients with known Gilbert's syndrome, direct bilirubin less or equal to 1.5 x ULN will be used as organ function criteria, instead of total bilirubin\n* Negative serum pregnancy test in women with childbearing potential (WOCBP) defined as not post-menopausal for 12 months or no previous surgical sterilization, within one week prior to initiation of treatment. WOCBP must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 12 weeks after the last dose of study drug to minimize the risk of pregnancy. WOCBP must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 12 weeks after the last dose of study drug to minimize the risk of pregnancy\n* A male subject of fathering potential must use an adequate method of contraception to avoid conception throughout the study and for up to 12 weeks after the last dose of study drug to minimize the risk of pregnancy. If the partner is pregnant or breastfeeding, the subject must use a condom\n* Patients must sign an informed consent and authorization indicating that they are aware of the investigational nature of this study and the known risks involved\n\nExclusion Criteria:\n\n* Concurrent severe and\u002For uncontrolled medical conditions which could compromise participation in the study such as unstable angina, myocardial infarction within 6 months, unstable symptomatic arrhythmia, uncontrolled diabetes, serious active or uncontrolled infection\n* Pregnancy (positive pregnancy test) or lactation\n* Known CNS (central nervous system) disease, except for treated brain metastasis. Treated brain metastases are defined as having no evidence of progression or hemorrhage after treatment and no ongoing requirement for dexamethasone, as ascertained by clinical examination and brain imaging (magnetic resonance imaging-MRI or computerized tomography-CT) during the screening period. Anticonvulsants (stable dose) are allowed. Treatment for brain metastases may include whole brain radiotherapy (WBRT), radiosurgery (RS; gamma knife, linear accelerator \\[LINAC\\], or equivalent) or a combination as deemed appropriate by the treating physician. Patients with CNS metastases treated by neurosurgical resection or brain biopsy performed within 3 months prior to day 1 will be excluded",{"count":201,"type":19},28,[22,83],"This phase I trial studies the best dose and side effects of mesenchymal stromal cells-derived exosomes with KrasG12D siRNA (iExosomes) in treating participants with pancreatic cancer with KrasG12D mutation that has spread to other places in the body. iExosomes may work better at treating pancreatic cancer.",[205,25,206,87],"KRAS NP_004976.2:p.G12D","Pancreatic Ductal Adenocarcinoma","2026-05-18",{"date":137,"type":30},{"date":210,"type":30},"2021-01-27",{"date":212,"type":19},"2027-04-30",{"name":36,"class":37},{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":20,"phases":223,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":235},"100598801","phase-2-evaluating-nalirifox-vs-modified-gemcitabine-nab-paclitaxel-and-cisplatin-in-patients-with-locally-advanced-and-metastatic-pancreatic-adenocarcinoma-100598801","NCT07076212","Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma","Phase II Study Evaluating NALIRIFOX Versus Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, aged ≥18 years\n* For females of reproductive potential: use of highly effective contraception for at least 1 month before screening and agreement to use such a method during study participation and for an additional 9 months after the end of the last dose of study medication administration\n* Female patients including WOCBP must test negative for pregnancy at the time of screening based on a urine or serum pregnancy test.\n* For males of reproductive potential: use of condoms or other methods to ensure effective contraception with a partner during the study and for 4 months after the last dose of study medication.\n* Histologically or cytologically confirmed locally advanced or metastatic PDAC that has not been previously treated\n* Radiographically confirmed measurable (per RECIST 1.1) locally advanced or metastatic PDAC per the National Comprehensive Cancer Network (NCCN) definition.\n* Inoperable status due to the presence of locally advanced, unresectable disease with or metastases.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Hematological, biochemical, and organ function inclusion criteria:\n\n  * Absolute neutrophil count (ANC) ≥1500\u002Fmm3 without the use of hemopoietic growth factors within 7 days before treatment\n  * Platelet count ≥100,000\u002Fmm3.\n  * International normalized ratio (INR) \\\u003C1.5 unless the patient is receiving anticoagulation therapy, in which case a therapeutic INR is acceptable. Anticoagulation therapy with low-molecular weight heparin or warfarin, whether medically indicated, is permitted.\n  * Adequate renal function, as evidenced by serum\u002Fplasma creatinine level \\\u003C1.6 mg\u002FdL\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Treatment with another investigational drug or other intervention within 30 days of protocol initiation.\n* Known hypersensitivity\u002Fallergic reaction to any of the components of the therapeutic agents in mGAP or NALIRIFOX.\n* Any other medical or social condition deemed by the investigator to be likely to interfere with a subject's ability to sign informed consent, cooperate, and participate in the study or who is likely to interfere with the interpretation of the results.\n* Unwilling or unable to comply with study procedures and\u002For study visits.\n* Uncontrolled, active infection\n* Histologic diagnosis other than adenocarcinoma.\n* Medical co-morbidities, that preclude major abdominal surgery",{"count":222,"type":19},52,[83],"This is a single-center, open-label, randomized Phase 2 trial to evaluate the efficacy of NALIRIFOX (Arm 1) vs mGAP (Arm 2) in previously untreated patients with locally advanced (unresectable) and metastatic pancreatic ductal adenocarcinoma (PDAC).",[25,112],"2026-05-04",{"date":228,"type":30},"2026-05-06",{"date":230,"type":30},"2026-04-02",{"date":232,"type":19},"2029-11",{"name":234,"class":37},"Medical University of South Carolina",2,{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":20,"phases":244,"briefSummary":245,"conditions":246,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":38},"100607487","phase-1-tr-002-for-the-treatment-of-advanced-unresectable-or-metastatic-solid-tumors-and-unresectable-or-metastatic-refractory-pancreatic-adenocarcinoma-100607487","NCT07189195","TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma","A Phase 1 Study of Bisaminoquinoline Derivative (TR-002) for Injection for Advanced Treatment-Refractory Solid Tumors","Inclusion Criteria:\n\n* Aged 18 or over at the time of consent\n* Pathology or histology-confirmed metastatic or unresectable solid tumor for which standard systemic treatments are no longer effective or not tolerated\n* For the expansion cohort, participants must have pathology or histology-confirmed metastatic or unresectable pancreatic adenocarcinoma that is refractory and\u002For intolerant to all standard-of-care systemic treatments (including gemcitabine, nab-paclitaxel, fluoropyrimidine, oxaliplatin, and irinotecan)\n* Participants in dose escalation may have measurable and\u002For non-measurable disease. Imaging for disease assessment of measurable and non-measurable disease must be completed within 28 days prior to registration. Participants in dose expansion must have measurable disease per Response Evaluation Criteira in Solid Tumors (RECIST) 1.1\n* Adequate cardiac function, assessed by multiple-gated acquisition (MUGA) scan or echocardiography (left ventricular ejection fraction of \\> 50%)\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2\n* Absolute neutrophil count ≥ 1,000\u002FmcL\n* Platelets ≥ 75,000\u002FmcL\n* Hemoglobin ≥ 8g\u002FdL\n* Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (\\\u003C 3 x ULN in patients with known Gilberts)\n* Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \\[SGOT\\])\u002F alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \\[SGPT\\]) ≤ 3 × institutional ULN (\\\u003C 5 x ULN in patients with known liver metastases)\n* Creatinine ≤ 1.5 x institutional ULN OR glomerular filtration rate (GFR) ≥ 60 mL\u002Fmin\u002F1.73 m\\^2\n* For people of reproductive potential: use of highly effective contraception for at least 1 month prior to enrollment and agreement to use such a method through 3 months following the last dose of study treatment\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n\nExclusion Criteria:\n\n* Lactating or pregnant patients or patients of reproductive potential not willing to use effective methods of contraception\n* Clinically significant toxicities from most recent therapy or intervention prior to study enrollment that have not resolved to baseline or grade 1 (exceptions include alopecia and grade 2 sensory neuropathy)\n* Participant with a history of the following significant cardiovascular disease will be excluded:\n\n  * Participant has a history of myocardial infarction or unstable angina within 6 months prior to day 1.\n  * Participant has New York Heart Association (NYHA) Class II or greater congetive heart failure (CHF).\n  * History of cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 6 months prior to study treatment.\n  * Participant has cardiac arrhythmia, complete left bundle branch block, obligate use of a cardiac pacemaker, long QT syndrome or right bundle branch block with left anterior hemiblock (bifascicular block).\n  * History of congenital long QT syndrome or prolonged corrected QT interval (QTc) \\> 470 msec for females and males using Fridericia's formula (unless a pacemaker is in place or additional clinically non-significant condition such as bundle-branch block necessitating use of an alternate formula per cardiologist calculation) or uncorrectable abnormalities in serum electrolytes (i.e., sodium, potassium, calcium, magnesium, phosphorus). An average of triplicate readings for assessing QTc interval may be used\n* Active bacterial, fungal, and viral infection, as documented by positive culture, radiological imaging techniques, septic fever, or septic shock symptoms\n* Known hypersensitivity to 4-aminoquinolone compounds\n* Retinal or visual field changes of any etiology\n* History of psoriasis\n* History of porphyria\n* Known glucose-6-phosphate dehydrogenase (G6PD) deficiency\n* History of seizure disorder\n* Any other condition that could compromise the subject's safety or put the study outcomes at undue risk",{"count":222,"type":19},[22],"This phase I trial tests the safety, side effects and best dose of TR-002 for the treatment of solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced), that cannot be removed by surgery (unresectable), that has spread from where it first started (primary site) to other places in the body (metastatic) and unresectable or metastatic pancreatic adenocarcinoma that does not respond to treatment (refractory). Chemotherapy drugs, such as TR-002, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. TR-002 may be safe and tolerable in treating patients with advanced, unresectable or metastatic solid tumors and unresectable or metastatic, refractory pancreatic adenocarcinoma.",[247,248,25,249,115,87,250,158],"Advanced Malignant Solid Neoplasm","Metastatic Malignant Solid Neoplasm","Refractory Pancreatic Adenocarcinoma","Unresectable Malignant Solid Neoplasm","2026-03-03",{"date":253,"type":30},"2026-03-05",{"date":255,"type":30},"2025-11-07",{"date":257,"type":19},"2030-02-07",{"name":259,"class":37},"University of California, Davis",{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":20,"phases":269,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":38},"100371345","phase-2-biologically-optimized-infusion-schedule-of-gemcitabine-and-nab-paclitaxel-for-the-treatment-of-metastatic-pancreatic-cancer-100371345","NCT04115163","Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer","A Pilot Study of Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma","Inclusion Criteria:\n\n* Participant has definitive histologically or cytologically confirmed adenocarcinoma of the pancreas. The definitive diagnosis of metastatic pancreatic adenocarcinoma will be made by integrating the histopathological data within the context of the clinical and radiographic data. Participants with islet cell neoplasms are excluded\n* Patient has one or more metastatic tumors measurable by computed tomography (CT) scan (or magnetic resonance imaging \\[MRI\\], if patient is allergic to CT contrast media or if the tumor is difficult to delineate on CT scan) as defined by RECIST 1.1 criteria\n* Non-pregnant and non-lactating\n\n  * If a female patient is of child-bearing potential, as evidenced by regular menstrual periods, she must have a negative serum pregnancy test beta-human chorionic gonadotropin (beta-hCG) documented 72 hours prior to the first administration of study drug\n  * The patient must agree to use a method of contraception considered highly effective by the investigator during the period of administration of study drug and after the end of treatment for an additional 3 months. Adequate birth control methods are defined below\n\n    * Women will be considered of childbearing potential unless surgically sterilized by hysterectomy or bilateral tubal ligation\u002Fsalpingectomy, or if they are post-menopausal (defined as absence of menses for at least 1 year). Sexually active men and women of childbearing potential who are sexually active and not willing to use a highly effective method of birth control during the trial and for at least three months after will be considered ineligible for the trial. A highly effective method of birth control is defined as one which results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or vasectomized partner. In the event that local regulations require additional restrictions to the above definition, the patient information will specify the acceptable contraceptive methods\n* Patients must have received no previous chemotherapy or investigational therapy for the treatment of metastatic pancreatic cancer. Prior adjuvant treatment is allowed as long as the last chemotherapy was \\> 6 months ago. Prior use of 5-fluorouracil (5-FU) or gemcitabine administered as a radiation sensitizer or in the adjuvant setting is allowed, provided at least 2 month have elapsed since completion of the last dose and no lingering significant toxicities are present. Prior radiation is allowed as long as the planned lesion(s) to be measured were not previously radiated\n* Absolute neutrophil count (ANC) \\>= 1.5 x 10\\^9\u002FL (obtained =\\\u003C 14 days prior to randomization)\n* Platelet count \\>= 100,000\u002Fmm\\^3 (100 x 10\\^9\u002FL) (obtained =\\\u003C 14 days prior to randomization)\n* Hemoglobin (Hgb) \\>= 9 g\u002FdL (obtained =\\\u003C 14 days prior to randomization)\n* Aspartate transaminase (AST), serum glutamic-oxaloacetic transaminase (SGOT), alanine transaminase (ALT) serum glutamic-pyruvic transaminase (SGPT) =\\\u003C 2.5 x upper limit of normal range (ULN), unless liver metastases are clearly present, then =\\\u003C 5 x ULN is allowed (obtained =\\\u003C 14 days prior to randomization)\n* Total bilirubin =\\\u003C 2 x ULN (obtained =\\\u003C 14 days prior to randomization)\n* Patient has Karnofsky performance status (KPS) \\>= 60 or Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Patient has been informed about the nature of the study, has agreed to participate in the study, and signed the informed consent form (ICF) prior to participation in any study-related activities\n\nExclusion Criteria:\n\n* Patient has known brain metastases, unless previously treated and well-controlled for at least 3 months (defined as clinically stable, no edema, no steroids and stable in 2 scans at least 4 weeks apart)\n* Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy\n* Patient has known active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C. HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial\n* Patient has a history of allergy or hypersensitivity to any of the study drugs or any of their excipients\n* Patient has serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders, which could compromise the patient's safety or the study data integrity based on the assessment of the enrolling physician\n* Patient is unwilling or unable to comply with study procedures",{"count":268,"type":19},67,[83],"This phase II trial studies how well a biologically optimized infusion schedule of gemcitabine and nab-paclitaxel works in treating patients with pancreatic cancer that has spread to other places in the body (metastatic). Drugs used in chemotherapy, such as gemcitabine and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Altering the timing of the nab-paclitaxel infusion may improve response in patients with pancreatic cancer.",[25,87],"2026-02-08",{"date":274,"type":30},"2026-02-11",{"date":276,"type":30},"2020-06-24",{"date":278,"type":19},"2026-12-31",{"name":280,"class":37},"Anne Noonan",{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":288,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":289,"targetDuration":4,"studyType":20,"phases":291,"briefSummary":293,"conditions":294,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":303},"100556428","telehealth-self-management-coaching-sessions-to-improve-quality-of-life-in-pancreatic-cancer-survivors-and-their-family-care-givers-100556428","NCT06524973","Telehealth Self-Management Coaching Sessions to Improve Quality of Life in Pancreatic Cancer Survivors and Their Family Care Givers","Impacting Quality of Life and Pancreatic Cancer Survivorship Through a Telehealth Intervention","Inclusion Criteria:\n\n* • PATIENT: Documented informed consent of the participant and\u002For legally authorized representative\n\n  * Assent, when appropriate, will be obtained per institutional guidelines\n\n    * PATIENT: Age: ≥ 18 years\n    * PATIENT: Eastern Cooperative Oncology Group (ECOG) ≤ 2\n    * PATIENT: Ability to read and understand English or Spanish for questionnaires\n    * PATIENT: Subjects must have histologically or cytologically confirmed diagnosis of metastatic pancreatic adenocarcinoma who are within 8 weeks of initial diagnosis\n    * FAMILY CARE GIVER: Documented informed consent of the participant and\u002For legally authorized representative\n  * Assent, when appropriate, will be obtained per institutional guidelines\n\n    * FAMILY CARE GIVER: Age: ≥ 18 years\n    * FAMILY CARE GIVER: Ability to read and understand English or Spanish for questionnaires\n    * FAMILY CARE GIVER: A family member or friend identified by the patient and defined as a person who knows the patient well and is involved in the patient's medical care\n\nExclusion Criteria:\n\n* • An employee who is under the direct\u002F indirect supervision of the principal investigator (PI)\u002F a co-investigator\u002F the study manager\n\n  * A direct study team member",true,{"count":290,"type":19},136,[292],"NA","This clinical trial evaluates the impact of telehealth self-management coaching sessions on quality of life in pancreatic cancer survivors and their family care givers (FCGs). Patients with pancreatic cancer experience many symptoms because of the disease and treatment, which can have a negative impact on quality of life. Patients and their families have unmet needs during treatment, including a lack of quality of life programs that offer support to patients. Supporting patients and families on managing the physical symptoms, emotional well-being, social well-being and spiritual well-being with telehealth self-management coaching sessions may help improve quality of life, manage symptoms from treatment, and support families in their role as caregivers during treatment.",[25],"2025-11-06",{"date":297,"type":30},"2025-11-10",{"date":299,"type":30},"2024-10-07",{"date":301,"type":19},"2027-05-03",{"name":145,"class":37},22,{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":4,"eligibilityCriteria":310,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":311,"targetDuration":4,"studyType":20,"phases":313,"briefSummary":314,"conditions":315,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":325},"100560359","phase-2-gemcitabine-nab-paclitaxel-plus-the-therabionic-p1-an-amplitude-modulated-radiofrequency-electromagnetic-fields-device-to-treat-metastatic-pancreatic-cancer-100560359","NCT06576115","Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer","Treatment of Patients With Metastatic Pancreatic Cancer With Gemcitabine and Nab-Paclitaxel and Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF)","Inclusion Criteria:\n\n* Patients must have histologically or cytologically proven advanced metastatic adenocarcinoma of the pancreas. Patients with mixed tumor with predominant adenocarcinoma pathology can be enrolled.\n* One or more measurable metastatic tumors per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) on imaging studies CT or MRI or PET scans\n* If female patient is of childbearing potential must have a negative serum pregnancy test (βhCG) documented up to 48 hrs prior to administration of chemotherapy.\n* Females of childbearing potential and males with female partners of childbearing potential, if sexually active, must agree to use two forms of contraception during the period of administration of study drug and up to 6 months after the end of treatment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.\n* Age above 18 years\n* Based on prior studies, patients 80 years of age and older are considered to be at higher risk for fatal neutropenic sepsis. These patients should be thoroughly evaluated including geriatric assessment prior to enrollment. Clinical judgment should be exercised regarding patients' susceptibility for sepsis or infection (presence of biliary tract infection, uncontrolled diabetes, etc.). The patients in this age group should be not enrolled should there be any concern for rapid deterioration of clinical and functional status.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Parameter Levels:\n\nAbsolute neutrophil count (ANC) ≥ 1,500\u002FmcL Platelets \\> 100,000\u002FmcL Total bilirubin ≤ 1.5 X institutional upper limit of normal AST(SGOT)\u002FALT(SGPT) \\\u003C 2.5 X ins Creatinine ≤ 1.5 X institutional upper limit of normal Or CrCL \\> 50\n\n* Ability to understand and the willingness to sign an IRB-approved informed consent document (either directly or via a legally authorized representative).\n\nExclusion Criteria:\n\n* Patients who have had chemotherapy with gemcitabine and\u002For nab-paclitaxel within six months prior to entering the study in the adjuvant or neo-adjuvant setting.\n* Patients receiving any other investigational agents.\n* Patients with known brain metastases are excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.\n* History of hypersensitivity or allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine and nab-paclitaxel.\n* No history of malignancy in last 3 years except cervical cancer in situ, adequately treated basal cell or squamous cell carcinoma of skin or treated low risk prostate cancer, who are considered to be eligible.\n* Patients receiving calcium channel blockers and any agent blocking L-type of T-type Voltage Gated Calcium Channels such as amlodipine, nifedipine, ethosuximide are not allowed in the study unless their medical treatment is modified to exclude calcium channel blockers prior to enrollment. (Refer to Appendix D for a comprehensive list of excluded medications)\n* Patients with active and uncontrolled bacterial, viral or fungal infection requiring systemic therapy. Patients can be reevaluated for the study if the infection is deemed to be under control and the systemic therapy is completed.\n* Uncontrolled intercurrent illness including, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements or could compromise patients' safety.\n* Patient with known diagnosis of interstitial lung disease, sarcoidosis, pulmonary fibrosis or pneumonitis.\n* Pregnant women are excluded from this study because of potential risk for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with chemotherapy and AM RF EMF, patients who are breastfeeding will be excluded to participate in this study.\n* Patient has localized resectable or locally advanced tumor.\n* Patients has undergone major surgery, other than diagnostic surgery or procedures, within 4 weeks prior to the treatment day.\n* Patients is unable to comply with study procedures or anticipating a situation that would result in a treatment break for 14 or more consecutive days after the start of the study.\n* Patient is enrolled in any other clinical interventional trial.",{"count":312,"type":19},30,[83],"The goal of this study is to learn if the combination of nab-paclitaxel, gemcitabine and an Amplitude-Modulated Radiofrequency Electromagnetic Fields device (Therabionic P1) is safe and effective for patients with adenocarcinoma of the pancreas.",[25],"2025-11-04",{"date":318,"type":30},"2025-11-05",{"date":320,"type":30},"2025-02-28",{"date":322,"type":19},"2027-07",{"name":324,"class":37},"Barbara Ann Karmanos Cancer Institute",7,{"id":327,"slug":328,"hasResults":11,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":20,"phases":335,"briefSummary":336,"conditions":337,"keywords":338,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":97},"100205744","phase-3-glufosfamide-versus-5-fu-in-second-line-metastatic-pancreatic-cancer-100205744","NCT01954992","Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer","A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Fluorouracil (5-FU) in Patients With Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine","Inclusion Criteria:\n\n* At least 18 years of age\n* Pancreatic adenocarcinoma proven either by histology (surgical biopsy) or cytology (CT- or endoscopic-guided)\n* Metastatic pancreatic cancer\n* Disease progression during or after treatment with gemcitabine (alone or in combination with other agents; at regular, not radiosensitizing, doses)\n* Measurable or nonmeasurable disease by RECIST criteria (at least one target or nontarget lesion)\n* Recovered from reversible toxicities of prior therapy\n* ECOG performance status 0-1\n* All women of childbearing potential and all men must agree to use effective means of contraception (surgical sterilization or the use of barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) from entry into the study through 6 months after the last dose of chemotherapy\n* Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's IRB\u002FEthics Committee\n\nExclusion Criteria:\n\n* More than one prior systemic therapy regimen for metastatic pancreatic cancer (radiosensitizing doses of 5-FU or gemcitabine at the time of initial radiotherapy do not count as a prior systemic therapy regimen)\n* Hormonal therapy, radiation therapy, biologic therapy, chemotherapy or other systemic antitumor therapy for pancreatic cancer within 14 days prior to Cycle 1 Day 1\n* Insulin-dependent diabetes mellitus (patients with type 2 diabetes controlled with oral glucose lowering agents and the occasional use of insulin are permitted in the study)\n* Symptomatic brain metastases (baseline CT scan is not required in asymptomatic patients)\n* Active clinically significant infection requiring antibiotics\n* Known HIV positive or active hepatitis B or C\n* Recent (one year) history or symptoms of cardiovascular disease (NYHA Class 2, 3, or 4), particularly coronary artery disease, arrhythmias or conduction defects with risk of cardiovascular instability, uncontrolled hypertension, clinically significant pericardial effusion, or congestive heart failure\n* No other active malignancies (other than treated non-melanoma skin cancer or treated in situ cancer) within the past year\n* Major surgery within 3 weeks of the start of study treatment, without complete recovery\n* Clinically significant abnormalities in laboratory test results (including complete blood count, chemistry panel including electrolytes, and urinalysis)\n\n  * Hemoglobin \\\u003C9 g\u002FdL (may receive transfusion or erythropoietin to maintain)\n  * ANC \\\u003C1500\u002FμL\n  * Platelet count \\\u003C100,000\u002FμL\n  * Total bilirubin \\> 1.5×ULN\n  * AST\u002FALT \\> 2.5-fold above ULN (\\>5-fold above ULN if liver metastases)\n  * Phosphorus \\\u003C LLN\n  * Potassium \\\u003C LLN\n  * Serum creatinine \\> 2 mg\u002FdL\n  * Creatinine clearance \\\u003C 60 mL\u002Fmin (calculated by Cockcroft-Gault formula)\n* Females who are pregnant or breast-feeding\n* Participation in an investigational drug or device study within 14 days of the first day of dosing on this study\n* Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the patient in this study\n* Any medical history, concurrent disease or concomitant medication which could reasonably predispose the patient to renal insufficiency while on study treatment\n* Contraindication or unwillingness to undergo multiple CT scans\n* Unwillingness or inability to comply with the study protocol for any other reason",{"count":334,"type":19},480,[49],"The study is designed to assess whether glufosfamide provides additional survival benefit as compared to bolus 5-FU in patients with metastatic pancreatic cancer who have already progressed or failed therapy on a gemcitabine based first line regimen.",[25],[339,340,341],"glufosfamide","5-FU","metastatic pancreatic adenocarcinoma","2024-12-30",{"date":344,"type":30},"2024-12-31",{"date":346,"type":4},"2014-04",{"date":348,"type":19},"2026-12",{"name":350,"class":71},"Eleison Pharmaceuticals LLC."]